KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 106 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,310,000 | -18.2% | 290,577 | 0.0% | 0.12% | -18.9% |
| Q2 2021 | $4,048,000 | -24.7% | 290,577 | 0.0% | 0.14% | -21.4% |
| Q1 2021 | $5,379,000 | +4.8% | 290,577 | 0.0% | 0.18% | +10.3% |
| Q4 2020 | $5,134,000 | +15.3% | 290,577 | 0.0% | 0.16% | +7.1% |
| Q3 2020 | $4,452,000 | -39.9% | 290,577 | 0.0% | 0.15% | -52.8% |
| Q2 2020 | $7,404,000 | +64.6% | 290,577 | 0.0% | 0.33% | +6.2% |
| Q1 2020 | $4,498,000 | +40.0% | 290,577 | 0.0% | 0.31% | +68.7% |
| Q4 2019 | $3,214,000 | +30.0% | 290,577 | 0.0% | 0.18% | +1.7% |
| Q3 2019 | $2,473,000 | -37.1% | 290,577 | 0.0% | 0.18% | -47.0% |
| Q2 2019 | $3,934,000 | -25.0% | 290,577 | 0.0% | 0.34% | -44.3% |
| Q1 2019 | $5,248,000 | -35.7% | 290,577 | 0.0% | 0.61% | -39.8% |
| Q4 2018 | $8,162,000 | -72.7% | 290,577 | -75.2% | 1.01% | -69.6% |
| Q3 2018 | $29,904,000 | +47.0% | 1,172,700 | 0.0% | 3.32% | +44.0% |
| Q2 2018 | $20,346,000 | – | 1,172,700 | – | 2.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
| Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
| Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
| AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
| Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
| RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
| ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
| Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |